|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.
Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive
breast cancer: Mature outcomes and new biologic correlates on Phase III Intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 2004;88(Suppl 1). No abstract available
Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract
Hayes DF et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357(15):1496-506. Abstract
Thor AD et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90(18):1346-60. Abstract
 |
 |
EDITOR'S NOTE
Bev, BETH, BEATRICE and the next big moment in oncology
research: NSABP-C-08
Neil Love, MD
- Select publication
INTERVIEWS
Daniel F Hayes, MD
- Select publications
John F Forbes, MD
- Select publications
Julie R Gralow, MD
- Select publications
John F R Robertson,
MB, ChB, BSc, MD
- Select publications
Roundtable Discussion
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
